Kane Biotech’s Antibiofilm Technologies Published in Two New Scientific Books

March 1, 2010

WINNIPEG, Manitoba (February 23, 2010) - Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce that the Company’s Research and Development (R&D) team has made contributions to two new scientific books. At the invitation of the publishers, Humana Press and Nova Science Publishers, respectively, Kane Biotech’s team has authored two book chapters reviewing their biofilm research methodology and the antibiofilm-antimicrobial technology development strategy for bacterial infection control.

The contributions included a chapter in the book “Antimicrobial Peptides: Methods and Protocols (Eds. Andrea Giuliani & Andrea C. Rinaldi, Chapter 24, 2010)” entitled “Antimicrobial and Antibiofilm Activity of Quorum Sensing Peptides and Peptide Analogues against Oral Biofilm Bacteria” by K. LoVetri and S. Madhyastha. The chapter provides a review of the assay methods used by Kane Biotech to test the inhibitory effects of quorum sensing peptides and their analogues on the growth and biofilm formation of oral bacteria.

Additionally, the Company’s R&D team contributed a chapter to the book “Biofouling: Types, Impact and Anti-Fouling (Eds. Jun Chan & Shing Wong, Chapter 4, 2010) entitled “Biofouling and Anti-fouling of Medical Devices” by K. LoVetri, P.V. Gawande, N. Yakandawala and S. Madhyastha. The chapter provides a review of Kane Biotech’s research related to developing antibiofilm-antimicrobial technologies.

“The invited contribution of chapters to these new books on biofilm-related research and solutions is recognition of Kane Biotech’s contributions to applied biofilm research and technology development,” stated Dr. Sri Madhyastha, VP-Research & Chief Scientific Officer of Kane Biotech. “We are proud of our recognized capability to develop antibiofilm-antimicrobial technologies based on sound science.”

“The chapters in these books contribute to the scientific awareness as well as knowledge of biofilm research and solutions,” stated Gord Froehlich, President and CEO of Kane Biotech. “It also acknowledges that Kane Biotech is a key player in developing antibiofilm-antimicrobial technologies for medical and industrial applications.”

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

For more information, please contact:
Gord Froehlich
President & Chief Executive Officer
Kane Biotech Inc.
204-477-7592 phone
204-453-1314 fax

Share This Story